Imiquimod - ≥98%, high purity , CAS No.99011-02-6, Agonist of TLR7

Item Number
I129798
Grouped product items
SKUSizeAvailabilityPrice Qty
I129798-50mg
50mg
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$39.90
I129798-100mg
100mg
In stock
$64.90
I129798-250mg
250mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$146.90
I129798-500mg
500mg
In stock
$148.90
I129798-1g
1g
In stock
$268.90
I129798-5g
5g
In stock
$1,206.90
I129798-25g
25g
In stock
$5,431.90

Toll-like receptor 7 agonist; immunomodulator

Basic Description

SynonymsHMS3715N19 | Imiquimod 100 microg/mL in Acetonitrile | Imiquimod- Bio-X | Aldara (TN) | DTXSID7041047 | HY-B0180 | S 26308 | AB00399298-05 | IMIQUIMOD [ORANGE BOOK] | YH44175 | 1-isobutylimidazo[4,5-c]quinolin-4-amine | HB3109 | IMIQUIMOD [JAN] | 4-Amino-
Specifications & PurityMoligand™, ≥98%
Biochemical and Physiological MechanismsToll-like receptor 7 agonist. Activates NF-κB and stimulates pro-inflammtory cytokines. Immunomodulator, antiviral and antitumor agent. Active in vivo and in vitro .
Storage TempStore at -20°C
Shipped InIce chest + Ice pads
GradeMoligand™
Action TypeAGONIST
Mechanism of actionAgonist of TLR7
NoteWherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Toxic, refer to SDS for further information. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
Product Description

Product Description

Imiquimod (R 837) is an immune response modifier that acts as a toll-like receptor 7 agonist.
A TLR7 activator and angiogenesis inhibitor.

Product Application

Imiquimod is a caspase 3 activator which acts as an immunomodulator and displays antiviral and anti-tumor activity. It is a patient-applied cream used for the treatment of genital warts and basal cell carcinoma. It is also used to cure actinic keratosis on the face and scalp. It belongs to a group of drugs called immune response modifiers, which work by activating the immune system to fight abnormal skin growth.

Associated Targets(Human)

NUDT1 Tchem 7,8-dihydro-8-oxoguanine triphosphatase (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
TLR7 Tclin Toll-like receptor 7 (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
PDE5A Tclin Phosphodiesterase 5A (5113 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
EGFR Tclin Epidermal growth factor receptor erbB1 (33727 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CA2 Tclin Carbonic anhydrase II (17698 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ESR1 Tclin Estrogen receptor alpha (17718 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HMGCR Tclin HMG-CoA reductase (2475 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NR3C1 Tclin Glucocorticoid receptor (14987 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
INSR Tclin Insulin receptor (5558 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PGR Tclin Progesterone receptor (8562 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADRB2 Tclin Beta-2 adrenergic receptor (11824 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CHRM2 Tclin Muscarinic acetylcholine receptor M2 (10671 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADRB1 Tclin Beta-1 adrenergic receptor (6630 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HTR1A Tclin Serotonin 1a (5-HT1a) receptor (14969 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADRA2A Tclin Alpha-2a adrenergic receptor (9450 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
AR Tclin Androgen Receptor (11781 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CHRM1 Tclin Muscarinic acetylcholine receptor M1 (12690 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ACE Tclin Angiotensin-converting enzyme (1423 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
DRD2 Tclin Dopamine D2 receptor (23596 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
GABRA1 Tclin GABA receptor alpha-1 subunit (399 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MAOA Tclin Monoamine oxidase A (11911 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CNR1 Tclin Cannabinoid CB1 receptor (20913 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
DRD1 Tclin Dopamine D1 receptor (9720 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
DRD4 Tchem Dopamine D4 receptor (7907 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ACHE Tclin Acetylcholinesterase (18204 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PTGS1 Tclin Cyclooxygenase-1 (9233 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SLC6A2 Tclin Norepinephrine transporter (10102 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HRH2 Tclin Histamine H2 receptor (5428 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADRA1D Tclin Alpha-1d adrenergic receptor (4171 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HTR1B Tclin Serotonin 1b (5-HT1b) receptor (2801 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HTR2A Tclin Serotonin 2a (5-HT2a) receptor (14758 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HTR2C Tclin Serotonin 2c (5-HT2c) receptor (11471 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
AVPR2 Tclin Vasopressin V2 receptor (2912 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADORA1 Tclin Adenosine A1 receptor (17603 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
AGTR1 Tclin Type-1 angiotensin II receptor (5176 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CALCR Tclin Calcitonin receptor (2215 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SLC6A4 Tclin Serotonin transporter (12625 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADRA1A Tclin Alpha-1a adrenergic receptor (8359 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PTGS2 Tclin Cyclooxygenase-2 (13999 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HRH1 Tclin Histamine H1 receptor (7573 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADRA1B Tclin Alpha-1b adrenergic receptor (2912 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
OPRM1 Tclin Mu opioid receptor (19785 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
DRD3 Tclin Dopamine D3 receptor (14368 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
AVPR1A Tclin Vasopressin V1a receptor (5412 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
OPRD1 Tclin Delta opioid receptor (15096 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
OPRK1 Tclin Kappa opioid receptor (16155 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HTR3A Tclin Serotonin 3a (5-HT3a) receptor (3366 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SLC6A3 Tclin Dopamine transporter (10535 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
GRIN1 Tclin Glutamate (NMDA) receptor subunit zeta 1 (122 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
KCNH2 Tclin HERG (29587 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HTR4 Tclin Serotonin 4 (5-HT4) receptor (2068 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CACNA1C Tclin Voltage-gated L-type calcium channel alpha-1C subunit (766 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Agtr2 Angiotensin II type 2 (AT-2) receptor (803 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Mc4r Melanocortin receptor 4 (1205 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Ltc4s Leukotriene C4 synthase (1 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Sigmar1 Sigma opioid receptor (160 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Npy1r Neuropeptide Y receptor type 1 (8 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Cckar Cholecystokinin A receptor (90 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Pde4d Phosphodiesterase 4D (4 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Nos2 Nitric oxide synthase, inducible (3573 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Mapk1 MAP kinase ERK2 (650 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Hdac6 Histone deacetylase 6 (222 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Mmp9 Matrix metalloproteinase 9 (38 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Plasmodium falciparum (966862 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Mus musculus (284745 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Rattus norvegicus (775804 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Hepatitis C virus (23859 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
rep Replicase polyprotein 1ab (378 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Tlr7 Toll-like receptor 7 (174 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Tlr7 TLR7 and TLR8 (70 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Glra2 Glycine receptor (1745 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SARS-CoV-2 (38078 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Names and Identifiers

Pubchem Sid488183396
Pubchem Sid Urlhttps://pubchem.ncbi.nlm.nih.gov/substance/488183396
IUPAC Name 1-(2-methylpropyl)imidazo[4,5-c]quinolin-4-amine
INCHI InChI=1S/C14H16N4/c1-9(2)7-18-8-16-12-13(18)10-5-3-4-6-11(10)17-14(12)15/h3-6,8-9H,7H2,1-2H3,(H2,15,17)
InChi Key DOUYETYNHWVLEO-UHFFFAOYSA-N
Canonical SMILES CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N
Isomeric SMILES CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N
WGK Germany 3
RTECS NJ5903450
PubChem CID 57469
Molecular Weight 240.31
Reaxy-Rn 7710060

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Find and download the COA for your product by matching the lot number on the packaging.

21 results found

Lot NumberCertificate TypeDateItem
B2309991Certificate of AnalysisNov 15, 2024 I129798
B2309953Certificate of AnalysisNov 15, 2024 I129798
B2309944Certificate of AnalysisNov 15, 2024 I129798
B2309964Certificate of AnalysisNov 07, 2024 I129798
B2309966Certificate of AnalysisNov 07, 2024 I129798
B2309986Certificate of AnalysisNov 07, 2024 I129798
J1810144Certificate of AnalysisJul 05, 2024 I129798
G2410613Certificate of AnalysisMar 12, 2024 I129798
G2410612Certificate of AnalysisMar 12, 2024 I129798
C2429503Certificate of AnalysisMar 12, 2024 I129798
C2429502Certificate of AnalysisMar 12, 2024 I129798
C2429505Certificate of AnalysisMar 12, 2024 I129798
C2429512Certificate of AnalysisMar 12, 2024 I129798
C2223364Certificate of AnalysisJan 04, 2024 I129798
E1810042Certificate of AnalysisOct 17, 2023 I129798
E1810043Certificate of AnalysisOct 07, 2023 I129798
G2103012Certificate of AnalysisApr 14, 2023 I129798
B2309982Certificate of AnalysisJan 03, 2023 I129798
L2312048Certificate of AnalysisJan 03, 2023 I129798
J1810143Certificate of AnalysisOct 15, 2022 I129798
C2223405Certificate of AnalysisDec 25, 2021 I129798

Show more⌵

Chemical and Physical Properties

SolubilitySoluble in DMSO (4 mg/ml ,warming to 60 °C for 15 minutes) DMF (1.5 mg/ml) at 37 °C, and water (slightly soluble) at 37 °C. Insoluble in ethanol.
Melt Point(°C)297~299℃

Safety and Hazards(GHS)

Pictogram(s) GHS06,   GHS07
Hazard Statements

H413:May cause long lasting harmful effects to aquatic life

Precautionary Statements

P273:Avoid release to the environment.

P501:Dispose of contents/container to ...

WGK Germany 3
RTECS NJ5903450
Reaxy-Rn 7710060
Merck Index 4922

Related Documents

Citations of This Product

1. Haifeng Ni, Sunxiang Qian, Jie Lu, Jie Feng, Xiao-zhou Mou, Jing Zhang.  (2023)  Natural Polysaccharide Delivery Platforms with Multiscale Structure Used for Cancer Chemoimmunotherapy.  MOLECULAR PHARMACEUTICS,    (28):   [PMID:37752866] [10.1021/acs.molpharmaceut.3c00633]
2. Lu Dehua, Xu Yanming, Yang Xiaodong, Li Ying, Li Mengqing, Zheng Yuanyuan, Wang Yuenan, Wang Weihu, Wang Shubin, Gao Jing, Liu Yajie.  (2023)  Neutrophil membrane-derived nanoparticle loading TLR7 agonists augments radiotherapy efficacy and boosts abscopal effect via regulating tumor microenvironment.  Cancer Nanotechnology,  14  (1): (1-18).  [PMID:] [10.1186/s12645-023-00193-8]
3. Hong Liu, Zhenfu Wen, Haolin Chen, Zeyu Yang, Zhicheng Le, Zhijia Liu, Yongming Chen, Lixin Liu.  (2022)  Nanoadjuvants Actively targeting lymph node conduits and blocking tumor invasion in lymphatic vessels.  JOURNAL OF CONTROLLED RELEASE,  352  (497).  [PMID:36341931] [10.1016/j.jconrel.2022.10.053]
4. Meiting Li, Yaqian Zhang, Xiaoge Zhang, Zhuoyin Liu, Junjie Tang, Miao Feng, Baizhu Chen, Dalin Wu, Jie Liu.  (2022)  Degradable Multifunctional Porphyrin-Based Porous Organic Polymer Nanosonosensitizer for Tumor-Specific Sonodynamic, Chemo- and Immunotherapy.  ACS Applied Materials & Interfaces,  14  (43): (48489–48501).  [PMID:36281484] [10.1021/acsami.2c14776]
5. Jiexin Li, He Ren, Yaping Sun, Gengqi Liu, Xingyue Yang, Qian Qiu, Yuanmeng Ding, Jonathan F. Lovell, Yumiao Zhang.  (2021)  Magnetic Metal Micelles for Enhanced Delivery of Self-Immolating CD8+ T-Cell Epitopes for Cancer Immunotherapy.  CHEMISTRY OF MATERIALS,  33  (24): (9780–9794).  [PMID:] [10.1021/acs.chemmater.1c03681]
6. Lili Cheng, Xiaoge Zhang, Junjie Tang, Qijun Lv, Jie Liu.  (2021)  Gene-engineered exosomes-thermosensitive liposomes hybrid nanovesicles by the blockade of CD47 signal for combined photothermal therapy and cancer immunotherapy.  BIOMATERIALS,  275  (120964).  [PMID:34147721] [10.1016/j.biomaterials.2021.120964]
7. Zhang Lirong, Zhang Jingjing, Xu Lixia, Zhuang Zijian, Liu Jingjin, Liu Suwan, Wu Yunchao, Gong Aihua, Zhang Miaomiao, Du Fengyi.  (2021)  NIR responsive tumor vaccine in situ for photothermal ablation and chemotherapy to trigger robust antitumor immune responses.  JOURNAL OF NANOBIOTECHNOLOGY,  19  (1): (1-16).  [PMID:34001148] [10.1186/s12951-021-00880-x]
8. Yuting Cao, Yan Zhou, Jinbin Pan, Xinyu Zhong, Jianmin Ding, Xiang Jing, Shao-Kai Sun.  (2021)  A general strategy towards an injectable microwave-sensitive immune hydrogel for combined percutaneous microwave ablation and immunotherapy.  CHEMICAL ENGINEERING JOURNAL,  422  (130111).  [PMID:] [10.1016/j.cej.2021.130111]
9. Fan Jiang, Binbin Ding, Shuang Liang, Yajie Zhao, Ziyong Cheng, Bengang Xing, Ping'an Ma, Jun Lin.  (2021)  Intelligent MoS2–CuO heterostructures with multiplexed imaging and remarkably enhanced antitumor efficacy via synergetic photothermal therapy/ chemodynamic therapy/ immunotherapy.  BIOMATERIALS,  268  (120545).  [PMID:33253965] [10.1016/j.biomaterials.2020.120545]
10. Zhaocheng Li, Jiyuan Gao, Zexing Xiang, Honglei Zhang, Yibei Wang, Xuefei Zhang.  (2020)  A pH-responsive polymer linked with immunomodulatory drugs: synthesis, characteristics and in vitro biocompatibility.  JOURNAL OF APPLIED TOXICOLOGY,  41  (5): (724-735).  [PMID:32776438] [10.1002/jat.4042]
11. Xiangbo Meng, Ke Wang, Lin Lv, Ye Zhao, Chen Sun, Lianjun Ma, Bin Zhang.  (2019)  Photothermal/Photodynamic Therapy with Immune-Adjuvant Liposomal Complexes for Effective Gastric Cancer Therapy.  PARTICLE & PARTICLE SYSTEMS CHARACTERIZATION,  36  (6): (1900015).  [PMID:] [10.1002/ppsc.201900015]

References

1. Haifeng Ni, Sunxiang Qian, Jie Lu, Jie Feng, Xiao-zhou Mou, Jing Zhang.  (2023)  Natural Polysaccharide Delivery Platforms with Multiscale Structure Used for Cancer Chemoimmunotherapy.  MOLECULAR PHARMACEUTICS,    (28):   [PMID:37752866] [10.1021/acs.molpharmaceut.3c00633]
2. Lu Dehua, Xu Yanming, Yang Xiaodong, Li Ying, Li Mengqing, Zheng Yuanyuan, Wang Yuenan, Wang Weihu, Wang Shubin, Gao Jing, Liu Yajie.  (2023)  Neutrophil membrane-derived nanoparticle loading TLR7 agonists augments radiotherapy efficacy and boosts abscopal effect via regulating tumor microenvironment.  Cancer Nanotechnology,  14  (1): (1-18).  [PMID:] [10.1186/s12645-023-00193-8]
3. Hong Liu, Zhenfu Wen, Haolin Chen, Zeyu Yang, Zhicheng Le, Zhijia Liu, Yongming Chen, Lixin Liu.  (2022)  Nanoadjuvants Actively targeting lymph node conduits and blocking tumor invasion in lymphatic vessels.  JOURNAL OF CONTROLLED RELEASE,  352  (497).  [PMID:36341931] [10.1016/j.jconrel.2022.10.053]
4. Meiting Li, Yaqian Zhang, Xiaoge Zhang, Zhuoyin Liu, Junjie Tang, Miao Feng, Baizhu Chen, Dalin Wu, Jie Liu.  (2022)  Degradable Multifunctional Porphyrin-Based Porous Organic Polymer Nanosonosensitizer for Tumor-Specific Sonodynamic, Chemo- and Immunotherapy.  ACS Applied Materials & Interfaces,  14  (43): (48489–48501).  [PMID:36281484] [10.1021/acsami.2c14776]
5. Jiexin Li, He Ren, Yaping Sun, Gengqi Liu, Xingyue Yang, Qian Qiu, Yuanmeng Ding, Jonathan F. Lovell, Yumiao Zhang.  (2021)  Magnetic Metal Micelles for Enhanced Delivery of Self-Immolating CD8+ T-Cell Epitopes for Cancer Immunotherapy.  CHEMISTRY OF MATERIALS,  33  (24): (9780–9794).  [PMID:] [10.1021/acs.chemmater.1c03681]
6. Lili Cheng, Xiaoge Zhang, Junjie Tang, Qijun Lv, Jie Liu.  (2021)  Gene-engineered exosomes-thermosensitive liposomes hybrid nanovesicles by the blockade of CD47 signal for combined photothermal therapy and cancer immunotherapy.  BIOMATERIALS,  275  (120964).  [PMID:34147721] [10.1016/j.biomaterials.2021.120964]
7. Zhang Lirong, Zhang Jingjing, Xu Lixia, Zhuang Zijian, Liu Jingjin, Liu Suwan, Wu Yunchao, Gong Aihua, Zhang Miaomiao, Du Fengyi.  (2021)  NIR responsive tumor vaccine in situ for photothermal ablation and chemotherapy to trigger robust antitumor immune responses.  JOURNAL OF NANOBIOTECHNOLOGY,  19  (1): (1-16).  [PMID:34001148] [10.1186/s12951-021-00880-x]
8. Yuting Cao, Yan Zhou, Jinbin Pan, Xinyu Zhong, Jianmin Ding, Xiang Jing, Shao-Kai Sun.  (2021)  A general strategy towards an injectable microwave-sensitive immune hydrogel for combined percutaneous microwave ablation and immunotherapy.  CHEMICAL ENGINEERING JOURNAL,  422  (130111).  [PMID:] [10.1016/j.cej.2021.130111]
9. Fan Jiang, Binbin Ding, Shuang Liang, Yajie Zhao, Ziyong Cheng, Bengang Xing, Ping'an Ma, Jun Lin.  (2021)  Intelligent MoS2–CuO heterostructures with multiplexed imaging and remarkably enhanced antitumor efficacy via synergetic photothermal therapy/ chemodynamic therapy/ immunotherapy.  BIOMATERIALS,  268  (120545).  [PMID:33253965] [10.1016/j.biomaterials.2020.120545]
10. Zhaocheng Li, Jiyuan Gao, Zexing Xiang, Honglei Zhang, Yibei Wang, Xuefei Zhang.  (2020)  A pH-responsive polymer linked with immunomodulatory drugs: synthesis, characteristics and in vitro biocompatibility.  JOURNAL OF APPLIED TOXICOLOGY,  41  (5): (724-735).  [PMID:32776438] [10.1002/jat.4042]
11. Xiangbo Meng, Ke Wang, Lin Lv, Ye Zhao, Chen Sun, Lianjun Ma, Bin Zhang.  (2019)  Photothermal/Photodynamic Therapy with Immune-Adjuvant Liposomal Complexes for Effective Gastric Cancer Therapy.  PARTICLE & PARTICLE SYSTEMS CHARACTERIZATION,  36  (6): (1900015).  [PMID:] [10.1002/ppsc.201900015]

Solution Calculators